Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
To accelerate future vaccine development, understanding the longer-term funding dynamics behind recent successes such as the USA’s Operation Warp Speed and the UK’s Vaccine Taskforce is imperative.
Amyloid deposits are present in the brains of cognitively impaired individuals, but also accumulate throughout the body. Some biotechs aim to keep these misfolded proteins in check to treat a range of diseases, including heart failure, ALS and Alzheimer’s disease.
Europe’s first field trial of gene-edited vines began in northern Italy on 30 September 2024. Developed by EdiVite, a spinoff from the University of Verona, these Chardonnay vines have undergone gene inactivation to enable them to better defend themselves against downy mildew, a major fungal disease. The trial is being conducted on university land, with plans to expand to another site in the Veneto region. Researchers aim to gather initial data by 2025, with the potential for experimental winemaking in 2026.
